daclatasvir

Also known as BMS-790052, BMS 790052, BMS790052, Dimethyl N,N'-(biphenyl-4,4'-diylbis{1H-imidazole-5,2-diyl-((2S)-pyrrolidine-2,1- diyl)((1S)-1-(1-methylethyl)-2-oxoethane-2,1-diyl)})dicarbamate, EBP 883, N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid C,C'-dimethyl ester, Daklinza

Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV). The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. It is taken by mouth.

In the Vinony graph

Within Vinony's link graph, daclatasvir is referenced by 112 other articles, and connects out to Hypericum perforatum, antiviral drug and rifampicin.

Vinony files it under Biphenyls, Carbamates and Chemicals using indexlabels.

Its subject is documented across 20 Wikipedia language editions.

Key facts

Drug.image: Daclatasvir.svg
Drug.image_class: skin-invert-image
Drug.width: 275
Drug.tradename: Daklinza
Drug.MedlinePlus: a615044
Drug.DailyMedID: Daclatasvir
Drug.pregnancy_AU: B3
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: J05
Drug.ATC_suffix: AP07
Drug.legal_AU: S4
Drug.legal_CA: Rx-only
Drug.legal_UK: POM
Drug.legal_US: Rx-only
Drug.legal_status: Rx-only
Drug.bioavailability: 67%
Drug.protein_bound: 99%
Drug.metabolism: CYP3A

via Wikipedia infobox

Chemical data

Formula: C40H50N8O6
Molecular weight: 738.9 g/mol
IUPAC name: methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
SMILES: CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChIKey: FKRSSPOQAMALKA-CUPIEXAXSA-N
XLogP: 5.1
Polar surface area: 175 Å²
H-bond donors: 4
H-bond acceptors: 8
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2014
Admin. routes: oral
Indications: hepatitis C virus infection, chronic hepatitis C virus infection, infection, hepatitis B virus infection

via ChEMBL · EBI

Research

1,557 papers

Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.Clinical pharmacokinetics · 2018
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.Expert opinion on pharmacotherapy · 2023
Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.The Journal of antimicrobial chemotherapy · 2021
Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.The Annals of pharmacotherapy · 2016
Daclatasvir for the treatment of chronic hepatitis C.Expert opinion on pharmacotherapy · 2015

via PubMed

Wikidata facts

Subclass of: heterocyclic compound
Mass: 738.385331
Has use: medication

Show 6 more facts

medical condition treated: hepatitis C
chemical formula: C₄₀H₅₀N₈O₆
isomeric SMILES: CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
canonical SMILES: CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
defined daily dose: 60
subject has role: antiviral drug

Sources (7)

via Wikidata · CC0

~14 min read